Amgen in its response to the Institute for Clinical and Economic Review’s (ICER) request for comment on its framework says it’s important the organization take a transparent and objective approach.
ICER issued a call for comments as it looks to update its 2020 Value Assessment Framework.
“The credibility and impact of ICER as an independent value assessment body seeking to provide evidence aimed at improving patient quality of care and dialogues on value, hinges on firm grounding in robust and transparent science, methods, and process,” Amgen states.
To read more on Amgen’s response, click here.
